Roche, the multinational healthcare company, has been actively engaged in several
significant market moves. A
dividend growth streak of 38 years continues, with the latest rise to CHF 9.70. The bio-pharma giant completed a
$1.5 billion acquisition of Poseida Therapeutics, further extending its influence in the healthcare industry. An
obesity drug collaboration with Zealand marked a bold stride into a market dominated by Novo Nordisk and Eli Lilly. The FDA has accepted an sNDA for
Gazyva in Lupus Nephritis treatment, marking another potential breakthrough for Roche. Despite these advances, the company's stock has
suffered declines resulting from concerns about the
side effects of its obesity drug trial. However, market experts share a positive outlook on Roche's
healthy balance sheet and future growth.
Analysts such as UBS and Deutsche Bank have upgraded their ratings and increased their price target for Roche stock.
Roche Stocks News Analytics from Thu, 16 May 2024 07:00:00 GMT to Fri, 28 Mar 2025 20:56:13 GMT -
Rating 6
- Innovation 2
- Rumor -2
